UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000039148
Receipt number R000044649
Scientific Title Identification of new biomarkers for intestinal barrier function
Date of disclosure of the study information 2020/01/19
Last modified on 2021/07/19 10:38:23

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Identification of new biomarkers for intestinal barrier function

Acronym

Identification of new biomarkers for intestinal barrier function

Scientific Title

Identification of new biomarkers for intestinal barrier function

Scientific Title:Acronym

Identification of new biomarkers for intestinal barrier function

Region

Japan


Condition

Condition

Healthy adults

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Identification of new biomarkers for intestinal barrier function

Basic objectives2

Others

Basic objectives -Others

Identification of new biomarkers

Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

To investigate the relationship between known biomarkers for intestinal barrier function and new biomarkers, such as novel compounds and intestinal microflora in biological samples, and to identify new biomarkers for intestinal barrier function.

Key secondary outcomes

To investigate the relationship subjects background, such as physical examination, blood parameters, survey, and intestinal barrier function.


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Sugar tolerance test:
After a single dose of sugar solution (lactulose 10 g, mannitol 5 g, sucrose 20 g), collect urine for 6 hours.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

60 years-old >

Gender

Male and Female

Key inclusion criteria

1. 20<= 60> year-old females and males
2. Subject must read and sign the informed consent form

Key exclusion criteria

1. History of gastrointestinal surgical procedures
2. Presence of galactosemia
3. Presence of diabetes
4. Presence of a allergy to food containing sugar alcohol
5. Subjects who routinely used pharmaceuticals
6. Pregnant women, lactating and possibly pregnant
7. Subjects who had participated in other clinical trials within the past month
8. Determined ineligible by the principal investigator or sub-investigator

Target sample size

100


Research contact person

Name of lead principal investigator

1st name Masashi
Middle name
Last name Morifuji

Organization

Meiji Co., Ltd.

Division name

Food Microbiology Research Laboratories, R&D Division

Zip code

192-0919

Address

1-29-1 Nanakuni, Hachiouji, Tokyo

TEL

042-632-5822

Email

masashi.morifuji@meiji.com


Public contact

Name of contact person

1st name Masashi
Middle name
Last name Morifuji

Organization

Meiji Co., Ltd.

Division name

Food Microbiology Research Laboratories, R&D Division

Zip code

192-0919

Address

1-29-1 Nanakuni, Hachiouji, Tokyo

TEL

042-632-5822

Homepage URL


Email

masashi.morifuji@meiji.com


Sponsor or person

Institute

Meiji Co., Ltd.

Institute

Department

Personal name



Funding Source

Organization

Meiji Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Meiji Institutional Review Board

Address

1-29-1 Nanakuni, Hachiouji, Tokyo

Tel

042-632-5900

Email

MEIJI.IRB@meiji.com


Secondary IDs

Secondary IDs

YES

Study ID_1

19112901

Org. issuing International ID_1

CPCC Institutional Review Board

Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

チヨダパラメディカルケアクリニック(東京都)


Other administrative information

Date of disclosure of the study information

2020 Year 01 Month 19 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

112

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2019 Year 12 Month 02 Day

Date of IRB

2019 Year 11 Month 29 Day

Anticipated trial start date

2020 Year 01 Month 19 Day

Last follow-up date

2021 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2020 Year 01 Month 14 Day

Last modified on

2021 Year 07 Month 19 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000044649


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name